The first, formal revision of specific guidelines, known as RECIST, used by clinicians to measure tumour size and response to treatment, has been published today (Tuesday 20 January) in a special issue of the European Journal of Cancer (the official journal of ECCO - the European CanCer Organisation) [1]. Complete news at...
PREVIEW: Please join us for lunch and a preview on 27 January 2009, 1 - 2.30pm, Breast Cancer Haven, Effie Road, London, SW6 1TB Speakers: Caroline Hoffman, Clinical Director, Breast Cancer Haven. Dr Andrew Vallance-Owen, Bupa's Group Medical Director. Professor Dudley Sinnett, Consultant Breast Surgeon. Complete news at...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug for treating stage IV malignant melanoma that can increase median overall survival when compared with standard of care dacarbazine (Bedford Laboratories' DTIC-Dome, generics) would earn a higher patient share in the U.S. (60 percent) than in Europe (40 percent), according to surveyed U.S. and European oncologists. Complete news at...
Dr Sarah Cant, Policy Manager at Breakthrough Breast Cancer, says: "This research, whilst interesting, is only relevant to a very small proportion of women - those with a strong family history but without a BRCA gene fault. The researchers suggest that these women could benefit from extra breast screening and taking tamoxifen to reduce their breast cancer risk. However, tamoxifen is not currently licensed for this use in the UK. Complete news at...
Researchers long ago established a link between inflammation, cancer and the compound nitric oxide, which may be produced when the immune system responds to bacterial infections, including those of the colon. However, the exact nature of the relationship was unknown - until now. Complete news at...
Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say. In the Feb. 15 issue of Cancer Research (available online Jan. 20), they report that RS5444, being tested in a Phase 1/2 clinical trial to treat anaplastic thyroid cancer, might be useful for treating other cancers. Complete news at...
A chemical commonly used in the manufacture of rubber products may cause cancer in workers regularly exposed to it, suggests research published ahead of print in Occupational and Environmental Medicine. The researchers base their findings on higher than expected rates of certain cancers, and deaths from the disease, among men working at a rubber chemicals plant in North Wales. Complete news at...
Subscribe to:
Posts (Atom)
